Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma

Michèle Welti; Phil F. Cheng; Joanna Mangana; Mitchell P. Levesque; Reinhard Dummer; Laurence Imhof

doi:10.18632/oncotarget.28496

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma

PDF | How to cite

Oncotarget. 2023; 14:836-836. https://doi.org/10.18632/oncotarget.28496

Metrics: PDF 536 views | ?

Michèle Welti^1,2, Phil F. Cheng^1,2, Joanna Mangana^1,2, Mitchell P. Levesque^1,2, Reinhard Dummer^1,2 and Laurence Imhof^1,2,3

¹Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland
²Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland
³Institute for Biomedical Engineering, ETH Zurich, Zurich 8092, Switzerland

Published: September 25, 2023

Copyright: © 2023 Welti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The melanoma registry database of the Department of Dermatology has been partially supported by an unrestricted grant to the University of Zurich from Amgen, Novartis, BMS, MSD and Pierre Fabre. The study itself required no external funding.

Original article: Oncotarget. 2022; 13:1370-1379. DOI: https://doi.org/10.18632/oncotarget.28333.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28496

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma